- Conditions
- Atopic Dermatitis
- Interventions
- RVT-501 0.5% topical ointment
- Drug
- Lead sponsor
- Dermavant Sciences GmbH
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 682
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dermatitis, Atopic
- Interventions
- Protopic, Corticosteroid, placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Irvine, California • Loma Linda, California + 18 more
- Conditions
- Atopic Dermatitis
- Interventions
- Tapinarof cream, 1%
- Drug
- Lead sponsor
- Organon and Co
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Thousand Oaks, California • Centennial, Colorado • Coral Gables, Florida + 6 more
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
- Device · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Months to 36 Months
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Boston, Massachusetts
- Conditions
- Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Radiotherapy Side Effect, Radiation Burn, Radiation Dermatitis, Radiotherapy; Complications
- Interventions
- Mepitel Film®
- Device
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Clairton, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Atopic Dermatitis
- Interventions
- Cetaphil Restoraderm, Standard of Care
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 1 Day to 3 Weeks
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Atopic Dermatitis, Healthy Children
- Interventions
- Hydration Sensor
- Device
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 172 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
- Interventions
- Advanced multi-component meditation practice
- Behavioral
- Lead sponsor
- Tobias Moeller-Bertram
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Palm Desert, California
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Placebo, Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 57
- States / cities
- North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3, Placebo - Part 1 Group 4, ISB 830 - Part 2 Group 5, Placebo - Part 2 Group 6
- Drug
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Clovis, California • Rolling Hills Estates, California + 29 more
- Conditions
- Atopic Dermatitis
- Interventions
- FB825 or Placebo in subcutaneous route, FB825 in intravenous route
- Drug
- Lead sponsor
- Oneness Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Target PharmaSolutions, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- Atopic Dermatitis, Pruritus
- Interventions
- Levocetirizine dihydrochloride (Xyzal), placebo
- Drug
- Lead sponsor
- Derm Research, PLLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Atopic Dermatitis
- Interventions
- DS107, Placebo
- Drug
- Lead sponsor
- DS Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 64 Years
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more
- Conditions
- Atopic Dermatitis
- Interventions
- SB414 2%, SB414 6%, Vehicle
- Drug
- Lead sponsor
- Novan, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 9
- States / cities
- Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more
- Conditions
- Atopic Dermatitis
- Interventions
- Soak and smear, Dry Smear
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 2 Weeks to 18 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Atopic Dermatitis
- Interventions
- Routine Care/Education, Psychoeducation/Coping Prevention
- Other · Behavioral
- Lead sponsor
- Seton Healthcare Family
- Other
- Eligibility
- 2 Months to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Barzolvolimab, Matching placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more
- Conditions
- Atopic Dermatitis
- Interventions
- GHZ339, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota